Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 20Lung Neoplasms 18Glioma 13Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Multiple Myeloma 10Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Mouth Neoplasms 9Colorectal Neoplasms 8Carcinoma, Renal Cell 8Ovarian Neoplasms 7Oropharyngeal Neoplasms 7Melanoma 7Laryngeal Neoplasms 7Glioblastoma 7Carcinoma, Hepatocellular 7Carcinoma 7Wilms Tumor 6Sarcoma 6Neuroblastoma 6Nasopharyngeal Carcinoma 6Medulloblastoma 6Lymphoma, Non-Hodgkin 6Fallopian Tube Neoplasms 6Triple Negative Breast Neoplasms 5Rhabdoid Tumor 5

Interventions

trastuzumab deruxtecan 1cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡